11.75% Vaccine Reverse Convertible Bond – available on secondary market

11.75% Vaccine Reverse Convertible Bond – available on secondary market

2-year term, fixed annual interest rate of 11.75% and a barrier being set at 55% of BioNTech and Moderna


The 11.75% Vaccine Reverse Convertible Bond combines two fixed interest payments of 11.75% with a partial safety mechanism for the invested capital down to the barrier of 55%. The interest amount is paid out annually, regardless of the performance of the two underlying (BioNTech SE and Moderna, Inc.).

The share basket of the Reverse Convertible Bond consists of two pharmaceutical companies, successfully launching a vaccine against COVID-19 on the market: 

  • BioNTech SE is a German biotechnology company listed on the stock exchange since the end of 2019. Biontech's focus is on mRNA-based drug discovery. As of early 2020, Biontech developed the BNT162b2 vaccine against the human coronavirus SARS-CoV-2, which will be packaged at Pfizer facilities for global use. 

  • Moderna, Inc. is a U.S. biotechnology company that specializes in the research and development of mRNA-based drugs. The company's CoV vaccine is also based on this technology and, like Pfizer's, has been shown to provide a high level of protection against infection. 

If the daily closing prices of the two underlying shares (BioNTech SE and Moderna, Inc.) always quote above the respective barrier of 55% during the observation period, or if the closing prices of each shares quote at or above their respective strike at the final valuation date, the certificate is redeemed at 100% of the nominal value. 
Otherwise, physical delivery of the share with the lowest performance is effected. 

The issue price amounts to 100 % (nominal value EUR 1,000) within the subscription period. Further information as well as the Key Information Document please find on Product Page.

Reverse Convertible Bonds - explained in an easy way

For any additional information you may require do not hesitate to contact us on +43 1 515 20-484.

The Team Structured Products of Raiffeisen Centrobank




Key facts:
  • Name: 11,75 % Impfstoff Aktienanleihe
  • ISIN: AT0000A2RZF6
  • Initial valuation date: Aug 03, 2021
  • Term: 1.5 year
    (Maturity date: Aug 04, 2023)
  • Listing: Vienna, Frankfurt, Stuttgart
This is advertising that does not constitute investment advice, an offer, a recommendation or an invitation to submit an offer. Comprehensive information about the financial instrument and its opportunities and risks - see approved (basis) prospectus (including all supplements), published under www.rcb.at/en/securitiesprospectus. Additional information also in the Key Information Document and under "Customer Information and Regulatory Issues" at www.rcb.at/customerinformation. The approval of the prospectus should not be construed as endorsement of this financial instrument by the authority (FMA). You are about to purchase a product that is not simple and difficult to understand. We recommend that you read the prospectus before making an investment decision. The investor bears the credit risk of Raiffeisen Centrobank AG (RCB) when purchasing the financial instrument. The certificate is subject to specific rules that may already be disadvantageous in case of a probable default of RCB (for example, suspension of interest payments) - see www.rcb.at/en/basag. Certificates issued by RCB are no financial products as defined in the Regulation (EU) 2019/2088.
The Structured Products Team
T: +43151520484
E: produkte(at)rcb.at